One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
Why the study?
Does transcatheter aortic valve implantation (TAVI) improve haemodynamic and functional outcomes in high-risk patients with severe aortic stenosis?
Population
130 high-risk patients with severe aortic stenosis (61 transfemoral, 69 transapical), aged 82.1 ± 5.5 years.
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
TF survival advantage may reflect baseline differences; leaves open randomized comparison of TAVI access routes in high-risk aortic stenosis.
Structured PICO
Does transcatheter aortic valve implantation (TAVI) improve haemodynamic and functional outcomes in high-risk patients with severe aortic stenosis?
P
Population
130 high-risk patients with severe aortic stenosis (61 transfemoral, 69 transapical), aged 82.1 ± 5.5 years.
I
Intervention
Transcatheter aortic valve implantation (TAVI) via transfemoral (TF) or transapical (TA) approach using the Edwards SAPIEN valve.
O
Outcome
Primary safety endpoints: 30 days and 6 months mortality. Primary efficacy endpoints: haemodynamic and functional improvement at 12 months.hard clinical
TAVI via transfemoral or transapical approach shows promising procedural success and functional improvement in high-risk patients with severe aortic stenosis, though survival differs by approach likely due to baseline risk differences.
Cite This Study
Lefèvre et al. (2010) studied this question.